| Dr Anish Kaushik Vani, MD | |
|
125 Queens Rd Ste 200, Charlotte, NC 28204-3215 | |
| (704) 343-9800 | |
| (704) 347-2011 |
| Full Name | Dr Anish Kaushik Vani |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 10 Years |
| Location | 125 Queens Rd Ste 200, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003227000 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 2021-01777 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Novant Health Presbyterian Medical Center | Charlotte, NC | Hospital |
| Novant Health Matthews Medical Center | Matthews, NC | Hospital |
| Novant Health Mint Hill Medical Center | Charlotte, NC | Hospital |
| Novant Health Huntersville Medical Center | Huntersville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novant Medical Group Inc | 1153234893 | 1996 |
| The Presbyterian Hospital | 1153231907 | 359 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306950282 PECOS PAC ID: 1153234893 Enrollment ID: O20040204001028 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Entity Name | The Presbyterian Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053365817 PECOS PAC ID: 1153231907 Enrollment ID: O20040223001121 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Entity Name | Novant Health Rowan Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508931544 PECOS PAC ID: 3375452519 Enrollment ID: O20040422001655 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Entity Name | Novant Health Matthews Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184782419 PECOS PAC ID: 6406845247 Enrollment ID: O20051114000445 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Entity Name | Novant Health Mint Hill Medical Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063910404 PECOS PAC ID: 8123374394 Enrollment ID: O20181018000540 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Entity Name | Novant Health Ballantyne Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760190607 PECOS PAC ID: 4880065143 Enrollment ID: O20230518003163 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anish Kaushik Vani, MD Po Box 60447, Charlotte, NC 28260-0447 Ph: (704) 343-9800 | Dr Anish Kaushik Vani, MD 125 Queens Rd Ste 200, Charlotte, NC 28204-3215 Ph: (704) 343-9800 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and major advance for the field of regenerative medicine.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).
Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.
"We can worry less that a newly created bird flu virus might kill tens or hundreds of millions of people if it escaped from the laboratory," a New York Times editorial states. "But there is still some residual danger. And we remain appalled at the slipshod way in which this research was authorized despite its potential dangers to public health and national security," the editorial continues.
› Verified 7 days ago
John Michael Fedor, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1237 Harding Pl, Ste 3100, Charlotte, NC 28204 Phone: 704-373-0212 | |
Dr. Michael Warren Smith, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6115 Park South Dr Ste 100, Charlotte, NC 28210 Phone: 704-554-8787 Fax: 704-554-8774 | |
William Lane Jr., MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-4490 | |
Dr. Alagusivakumari Rameshbabu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10648 Park Rd, Charlotte, NC 28210 Phone: 704-667-8050 | |
Shibin Thomas Jacob, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 101 E W T Harris Blvd, Bldg 5000 Suite #5101, Charlotte, NC 28262 Phone: 704-863-5847 | |
Oscar Sven Brann, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6060 Piedmont Row Dr S Fl 10, Charlotte, NC 28287 Phone: 704-489-3094 |